BioTuesdays

Category - Feature

Season’s Greetings (and JPM 2016)

Wow, what an interesting year 2015 has turned out to be! Everyone at BioTuesdays would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be...

In conversation with Kevin Smith

As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and executing the company’s global...

Oramed sees value creating events through 2016

By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for...

Concert starts multiple dose trial with CF drug

By Len Zehr Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation...

Viking Therapeutics to complete two POC trials in 2016

By Len Zehr Viking has successfully completed three Phase 1 studies with VK5211, including a 21-day ascending dose study. Viking Therapeutics (NASDAQ:VKTX) expects to complete two proof-of-concept Phase 2 trials in 2016...

CRH Medical to consolidate GI anesthesia market

By Len Zehr With four acquisitions and a joint venture under its belt over the past 10 months, CRH Medical (NYSE MKT:CRHM; TSX:CRH) is in talks to continue consolidating the large and fragmented market of...

In conversation with Arun Menawat

As president and CEO of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ), Arun Menawat has led the company through a strategic transformation this year into a direct sales company from one originally dependent on partners to...